dGH Screen allows researchers to visualize the structure of the human genome and discover variations in a completely de novo fashion at a resolution of 5 kilobases, the company said. Importantly, the technology does not require bioinformatic methods to recalculate structure from pooled, digested DNA, which often leads to false negative and false positive results for structural variation.
KromaTiD has signed deals with several partners conducting preliminary studies analyzing genomic structural variation in a variety of contexts, including rare disease, radiation exposure, and CRISPR Cas-9 genome editing.
KromaTiD's dGH Screen is available for researchers developing therapies based on CRISPR-Cas9 and other gene editing systems, screening patients for the root causes of rare diseases or hematological cancers, and for qualifying the products of cellular engineering methods.
Copyright © 2021 scienceboard.net